[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Jones GL, Taylor PR, Windebank KP, Hoye NA, Lucraft H, Wood K, Angus B, Proctor SJ: Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents. Br J Cancer; 2007 Jul 2;97(1):29-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.
  • The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period.
  • Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL).
  • Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index >or=0.5).
  • They received PVACEBOP multi-agent chemotherapy as primary therapy.
  • Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16.
  • Five- and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / therapeutic use. Cohort Studies. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Male. Survival Analysis. Treatment Outcome. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Eur J Cancer. 1991;27(5):624-9 [1828974.001]
  • [Cites] QJM. 1998 Feb;91(2):131-9 [9578895.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2058-63 [10070311.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):670-5 [16007600.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2520-6 [16735704.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3736-44 [10577845.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1500-7 [10735898.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):397-403 [10917558.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2160-6 [7523608.001]
  • [Cites] Eur J Cancer. 1994;30A(7):1045-6 [7946575.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):812-8 [7717448.001]
  • [Cites] Bone Marrow Transplant. 1995 Dec;16(6):777-82 [8750269.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2622-30 [9215833.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):803-12 [11714108.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):795-806 [11937314.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3088-94 [12118022.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1579-85 [15370209.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):949-59 [7042093.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2547-56 [4052932.001]
  • [Cites] J Clin Oncol. 1987 May;5(5):742-9 [3572464.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1845-50 [3058876.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • (PMID = 17533403.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Other-IDs] NLM/ PMC2359673
  •  go-up   go-down


2. Natkunam Y, Stanton TS, Warnke RA, Horning SJ: Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab. Clin Lymphoma; 2001 Dec;2(3):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
  • A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma.
  • While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's and non-Hodgkin's lymphomas from which they must be distinguished for diagnosis and treatment.
  • We present an unusual case of a 30-year-old man with recurrent TCRBCL arising from lymphocyte-predominant Hodgkin's disease with remarkable response to treatment with the anti-CD20 antibody, rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunophenotyping. Liver / drug effects. Liver / pathology. Liver / radiography. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab. Spleen / drug effects. Spleen / pathology. Spleen / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11779297.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
3. Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, Hurwitz CA, Krasin M, Kun LE, Marcus KC, Tarbell NJ, Young JA, Hudson MM: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol; 2007 Jan 20;25(3):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
  • PURPOSE: To evaluate outcome and assess complications in children and adolescents with low-risk Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) chemotherapy and low-dose, involved-field radiation therapy (IFRT).
  • PATIENTS AND METHODS: One hundred ten children with low-risk Hodgkin's disease were treated with four cycles of VAMP and 15 Gy IFRT for those who achieved a complete response (CR) or 25.5 Gy for those with a partial response after two cycles of VAMP.
  • Factors contributing to 10-year EFS were: early CR (P = .02), absence of B symptoms (P = .01), lymphocyte predominant histologic subtype (P = .04), and less than three initial sites of disease (P = .02).
  • Pediatric patients with low-risk Hodgkin's disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, extended-field radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Doxorubicin / therapeutic use. Female. Humans. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use. Risk Factors. Survival Analysis. Treatment Outcome. Vinblastine / therapeutic use






Advertisement